Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Efficacy of Conversion Surgery Following Apatinib Plus Paclitaxel/S1 for Advanced Gastric Cancer With Unresectable Factors: A Multicenter, Single-Arm, Phase II Trial

Objective: Conversion therapy (surgical resection after chemotherapy) is a promising option for unresectable gastric cancer (GC) patients. Addition of anti-angiogenesis drug improves response to chemotherapy. Hence, this study explored the feasibility and efficacy of preoperative paclitaxel (PTX)/S1...

Full description

Bibliographic Details
Main Authors:	Zhiyuan Xu, Can Hu, Jianfa Yu, Yian Du, Ping Hu, Guofa Yu, Conggang Hu, Yu Zhang, Wei Mao, Shanqi Chen, Xiangdong Cheng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-03-01
Series:	Frontiers in Pharmacology
Subjects:	gastric cancer conversion surgery apatinib safety unresectable abdominal neoplasms
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.642511/full

Similar Items

Short-term survival and safety of apatinib combined with oxaliplatin and S-1 in the conversion therapy of unresectable gastric cancer
by: Zaisheng Ye, et al.
Published: (2021-06-01)

Phase 1 trial of apatinib combined with intensity-modulated radiotherapy in unresectable hepatocellular carcinoma
by: Hongzhi Wang, et al.
Published: (2022-07-01)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
by: Xu Z, et al.
Published: (2019-05-01)

Efficacy and Safety of Apatinib in Treatment of Unresectable Intrahepatic Cholangiocarcinoma: An Observational Study
by: Hu Y, et al.
Published: (2020-07-01)

Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study
by: Dailong Li, et al.
Published: (2022-08-01)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
by: Zhang W, et al.
Published: (2021-07-01)

Efficacy and safety of apatinib alone or apatinib plus paclitaxel/docetaxel versus paclitaxel/docetaxel in the treatment of advanced non‐small cell lung cancer: A meta‐analysis
by: Zhe Li, et al.
Published: (2021-11-01)

Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial
by: Zhengbo Song, et al.
Published: (2022-05-01)

Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study
by: Liang Yin, et al.
Published: (2023-05-01)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
by: Taojun Gong, et al.
Published: (2022-11-01)

Transarterial chemoembolization plus apatinib with or without camrelizumab for unresected hepatocellular carcinoma: A two-center propensity score matching study
by: Di Zhu, et al.
Published: (2022-11-01)

An exploratory clinical trial of apatinib combined with intensity‐modulated radiation therapy for patients with unresectable hepatocellular carcinoma
by: Hu Qiu, et al.
Published: (2023-01-01)

Case report: Long-term partial response of apatinib plus paclitaxel as second-line therapy in a patient with metastatic gastric cancer
by: Shengya Fu, et al.
Published: (2022-08-01)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020-09-01)

Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients
by: Hui Yao, et al.
Published: (2021-04-01)

Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study
by: Ning Li, et al.
Published: (2021-09-01)

The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01)

Prognostic nomogram for patients with unresectable pancreatic cancer treated with gemcitabine plus nab–paclitaxel or FOLFIRINOX: A post–hoc analysis of a multicenter retrospective study in Japan (NAPOLEON study)
by: Taro Shibuki, et al.
Published: (2022-01-01)

Resection of unresectable hepatocellular carcinoma after conversion therapy with apatinib and camrelizumab: a case report and literature review
by: Xin-Liang Liu, et al.
Published: (2024-03-01)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
by: Qi Li, et al.
Published: (2022-02-01)

Unresectable hepatoblastoma: current perspectives
by: Trobaugh-Lotrario AD, et al.
Published: (2017-02-01)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
by: Mingtao Liu, et al.
Published: (2020-04-01)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
by: Jiaqiang Wang, et al.
Published: (2023-11-01)

Study protocol: A single‐arm, multicenter, phase II trial of camrelizumab plus apatinib for advanced nonsquamous NSCLC previously treated with first‐line immunotherapy
by: Puyuan Xing, et al.
Published: (2021-10-01)

Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
by: Xie L, et al.
Published: (2020-01-01)

Efficacy and safety of the combination of camrelizumab and apatinib in the treatment of liver cancer: a systematic review and single-arm meta-analysis
by: Min Chen, et al.
Published: (2024-01-01)

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
by: Yue Hu, et al.
Published: (2020-08-01)

COMPARATIVE STUDY OF CONCURRENT CHEMORADIATION USING PACLITAXEL IN TWO HISTOPATHOLOGICAL SUBTYPES (SQUAMOUS CELL CARCINOMA/ADENOCARCINOMA) OF UNRESECTABLE NON-SMALL CELL LUNG CANCER
by: D. L. Nongrum, et al.
Published: (2022-04-01)

A Phase II, Single-Arm Study of Apatinib and Oral Etoposide in Heavily Pre-Treated Metastatic Breast Cancer
by: Nanlin Hu, et al.
Published: (2021-02-01)

A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas
by: Yan Zhou, et al.
Published: (2023-11-01)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
by: Yingying Du, et al.
Published: (2020-07-01)

The effect of icotinib or apatinib on the pharmacokinetic profile of oxycodone in rats and the underlying mechanism
by: Qi Zhou, et al.
Published: (2023-12-01)

Microwave ablation combined with apatinib and camrelizumab in patients with advanced hepatocellular carcinoma: A single-arm, preliminary study
by: Xin Li, et al.
Published: (2022-10-01)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
by: Zhou Ling, et al.
Published: (2023-03-01)

Apatinib treatment for KIT- and KDR-amplified angiosarcoma: a case report
by: Lishu Yang, et al.
Published: (2018-05-01)

Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
by: Guohu Han, et al.
Published: (2023-07-01)

Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
by: Su-su Bao, et al.
Published: (2023-09-01)

Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
by: Yunyan Mo, et al.
Published: (2024-01-01)

Clinical observation of apatinib in the treatment of metastatic colorectal cancer
by: CHEN Zhu, LIU Yan, GAO Li-hua, CHEN Bu-you, TANG Ai-hua, LIU Jun
Published: (2021-12-01)

Apatinib in the treatment of advanced non-small-cell lung cancer: A meta-analysis
by: Guo-Can Yu, et al.
Published: (2019-08-01)